Axsome Executive's $2.2M Stock Sales Signal Planned Portfolio Management

Rhea-AI Filing Summary

Form 144 Notice of Proposed Sale filed for Axsome Therapeutics (NASDAQ: AXSM) details insider trading activity. The filing indicates a proposed sale of 7,500 shares of common stock with an aggregate market value of $756,729, to be executed through Charles Schwab & Co.

The securities were acquired through an employee stock option exercise on June 18, 2025, with payment made via a cashless exercise through broker payment. The filing reveals recent trading activity by the same insider, Hunter R. Murdock, who sold:

• 7,500 shares on June 16, 2025, generating proceeds of $768,154
• 7,500 shares on June 17, 2025, generating proceeds of $751,975

The company currently has 49,236,365 shares outstanding. This Form 144 represents the seller's declaration that they are unaware of any material adverse non-public information regarding the company's operations.

Positive

• None.

Negative

• Insider Hunter R. Murdock has sold a total of 22,500 shares over three transactions in June 2025, with total proceeds of approximately $2.28M, indicating consistent selling pressure from management

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	7500	756729.00	49236365	06/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/18/2025	Employee Stock Option Exercise	Axsome Therapeutics, Inc.			7500	06/18/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hunter R. Murdock ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	06/16/2025	7500	768154.00
Hunter R. Murdock ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	06/17/2025	7500	751975.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares of AXSM stock were sold by Hunter R. Murdock in June 2025?

According to the Form 144 filing, Hunter R. Murdock sold a total of 15,000 AXSM shares in two transactions: 7,500 shares on June 16, 2025 for gross proceeds of $768,154, and another 7,500 shares on June 17, 2025 for gross proceeds of $751,975.

What is the proposed sale amount for AXSM stock in the latest Form 144 filing?

The Form 144 filing indicates a proposed sale of 7,500 shares of AXSM common stock with an aggregate market value of $756,729.00, to be executed through Charles Schwab & Co., Inc. on the NASDAQ exchange around June 18, 2025.

How did Hunter R. Murdock acquire the AXSM shares being sold?

The shares were acquired through an Employee Stock Option Exercise on June 18, 2025. The payment was made through a Broker Payment for Cashless Exercise arrangement with Axsome Therapeutics, Inc.

What is the total number of outstanding AXSM shares according to the Form 144?

According to the Form 144 filing, Axsome Therapeutics, Inc. (AXSM) has 49,236,365 shares outstanding.

What was the average selling price of AXSM shares in the insider's previous transactions?

Based on the reported transactions, the average selling price can be calculated from the two prior sales: June 16 sale averaged $102.42 per share ($768,154/7,500 shares) and June 17 sale averaged $100.26 per share ($751,975/7,500 shares).